Should treatment of Parkinson's disease be started with a dopamine agonist?
暂无分享,去创建一个
[1] A. Björklund,et al. Short-Term GDNF Treatment Provides Long-Term Rescue of Lesioned Nigral Dopaminergic Neurons in a Rat Model of Parkinson’s Disease , 1996, The Journal of Neuroscience.
[2] F. Hefti,et al. Toxicity of 6‐hydroxydopamine and dopamine for dopaminergic neurons in culture , 1990, Journal of neuroscience research.
[3] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[4] Bromocriptine in Parkinson's disease: a double-blind study comparing "low-slow" and "high-fast" introductory dosage regimens in de novo patients. UK Bromocriptine Research Group. , 1989, Journal of neurology, neurosurgery, and psychiatry.
[5] M. Mena,et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L‐DOPA toxicity , 1996, Neuroreport.
[6] L. Carr,et al. NF-Y activates mouse tryptophan hydroxylase transcription , 1995, Brain Research.
[7] C. Clarke. Does levodopa therapy delay death in Parkinson's disease? A review of the evidence , 1995, Movement disorders : official journal of the Movement Disorder Society.
[8] S. Kaveri,et al. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. , 1994, Journal of neurology, neurosurgery, and psychiatry.
[9] J. Guérit. Movement disorders. Neurologic Principles and Practice, R.L. Watts, W.C. Koller. McGraw Hill, New York (1997), 780 , 1999 .
[10] C. Nienaber,et al. The diagnosis of thoracic aortic dissection by noninvasive imaging procedures. , 1993, The New England journal of medicine.
[11] H. M. Geller,et al. l‐DOPA Cytotoxicity to PC12 Cells in Culture Is via Its Autoxidation , 1995, Journal of neurochemistry.
[12] W. Koller. Selegiline monotherapy in the treatment of Parkinson's disease , 1996, Neurology.
[13] Y. Agid,et al. Absence of neurotoxicity of chronic L‐DOPA in 6‐hydroxydopaminelesioned rats , 1997, Neuroreport.
[14] M. Kohno,et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.
[15] M. Laga. Interactions between STDs and HIV infection. , 1992, STD bulletin.
[16] David L. Felten,et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats , 1992, Neurobiology of Aging.
[17] C. Marsden,et al. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. , 1986, Movement disorders : official journal of the Movement Disorder Society.
[18] M. Mena,et al. Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants , 1995, Brain Research.
[19] S. Bloom,et al. Searching for gastrinomas. , 1993, BMJ.
[20] I. Ziv,et al. Dopamine-induced, genotoxic activation of programmed cell death. A role in nigrostriatal neuronal degeneration in Parkinson's disease? , 1996, Advances in neurology.
[21] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[22] C. Marsden,et al. Cabergoline in the treatment of early parkinson's disease , 1997, Neurology.
[23] K. Hodges. Census 2000 planning. , 1993, Applied demography.
[24] J. Bhawan,et al. Chronic dopa feeding of mice , 1982, Neurology.
[25] Richard S. J. Frackowiak,et al. Evidence for long‐term survival and function of dopaminergic grafts in progressive Parkinson's disease , 1994, Annals of neurology.
[26] K. Steece-Collier,et al. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdrawal of chronic dosing , 1995, Brain Research.
[27] M. Hallett,et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.
[28] P. Jenner,et al. Suppressive effect of L‐dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6‐hydroxydopamine , 1993, Movement disorders : official journal of the Movement Disorder Society.
[29] P R Sanberg,et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. , 1995, The New England journal of medicine.
[30] S. Mukherji. International migration in India: levels, trends and policy implications. , 1994, IIPS newsletter.
[31] O. Rascol,et al. Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study , 1998, Movement disorders : official journal of the Movement Disorder Society.
[32] A. Rascol,et al. Early treatment with a combination of bromocriptine and levodopa compared with levodopa monotherapy in the treatment of Parkinson's disease , 1989 .
[33] R. Nemni,et al. Evidence of peripheral axonal neuropathy in primary restless legs syndrome , 1995, Movement disorders : official journal of the Movement Disorder Society.
[34] Björn Gustavii,et al. Short‐ and long‐term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease , 1997, Annals of neurology.
[35] S. Fahn,et al. Antiparkinsonian therapies and brain mitochondrial complex I activity , 1995, Movement disorders : official journal of the Movement Disorder Society.